Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Alphamab Oncology's yield on cost for the quarter that ended in Dec. 2025 was 0.00.
The historical rank and industry rank for Alphamab Oncology's 5-Year Yield-on-Cost % or its related term are showing as below:
STU:3NK's 5-Year Yield-on-Cost % is not ranked *
in the Biotechnology industry.
Industry Median: 1.59 * Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.
Alphamab Oncology 5-Year Yield-on-Cost % Related Terms
STU:3NK vs VRTX, REGN, RVMD: 5-Year Yield-on-Cost % Comparison
For the Biotechnology subindustry, Alphamab Oncology's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Alphamab Oncology 5-Year Yield-on-Cost % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Alphamab Oncology's 5-Year Yield-on-Cost % distribution charts can be found below:
* The bar in red indicates where Alphamab Oncology's 5-Year Yield-on-Cost % falls into.
Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.
Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.
Alphamab Oncology (STU:3NK) has a 5-Year Yield-on-Cost % of 0.00 as of Aug. 20, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Alphamab Oncology and its competitors. According to the industry distribution chart, Alphamab Oncology ranks #999999 out of 149 companies in the Biotechnology industry.
Is Alphamab Oncology's 5-Year Yield-on-Cost % too high?
Alphamab Oncology's current 5-Year Yield-on-Cost % is 0.00. Based on the distribution chart, Alphamab Oncology ranks #999999 out of 149 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Alphamab Oncology has a GF Score™ of 55/100, reflecting its overall financial health beyond just this single metric.
How does Alphamab Oncology's 5-Year Yield-on-Cost % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Alphamab Oncology ranks #999999 out of 149 companies for 5-Year Yield-on-Cost %. This places Alphamab Oncology in the lower half of its industry. The industry median 5-Year Yield-on-Cost % is 1.59. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Biotechnology company?
The median 5-Year Yield-on-Cost % among Biotechnology companies is 1.59, based on 149 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Alphamab Oncology and its competitors. For the Biotechnology industry, the median 5-Year Yield-on-Cost % is 1.59 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Alphamab Oncology's current 5-Year Yield-on-Cost % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alphamab Oncology stock overvalued right now?
Alphamab Oncology (STU:3NK) has a current 5-Year Yield-on-Cost % of 0.00. The stock's GF Value™ is €0.83, compared to a current price of €0.89 — trading 7.2% above its estimated fair value. The current 5-Year Yield-on-Cost % is 0.00. Alphamab Oncology's overall GF Score™ is 55/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For Alphamab Oncology (STU:3NK), the current 5-Year Yield-on-Cost % is 0.00 as of Aug. 20, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Alphamab Oncology (STU:3NK) Overvalued in 2026?
Based on GuruFocus' analysis, Alphamab Oncology stock appears to be overvalued.
The current stock price of €0.89 is trading 7.2% above its estimated GF Value™ of €0.83.
Key valuation signals for STU:3NK:
5-Year Yield-on-Cost %: 0.00
GF Value™: €0.83 vs. price of €0.89 (7.2% above fair value)
No single metric tells the full story. See the STU:3NK stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Alphamab Oncology is a biopharmaceutical company in China with a fully integrated proprietary technology platform in ADCs, bispecific antibodies, and multifunctional protein engineering. The Company is principally engaged in the research and development, manufacturing, and commercialisation of biologics of oncology. It delivers therapeutic biologics by applying its drug discovery and development capabilities. Its product portfolio includes Envafolimab (KN035), KN026, JSKN003, JSKN016, JSKN033, JSKN022, JSKN027, JSKN021, KN019, and KN046.
55GF Score
Get the complete analysis for STU:3NK
5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:3NK has been successfully added to your 
